Neil McFarlane has served as president, chief executive officer, and a director of Zevra Therapeutics since October 2023. McFarlane served as a member of the board of directors of Collegium Pharmaceutical between April 2022 and July 2024. Previously, McFarlane served as the CEO and a member of the board of directors of Adamas Pharmaceuticals from September 2019 until its acquisition by Supernus Pharmaceuticals in November 2021. McFarlane worked as an independent consultant between June 2019 and August 2019 and between December 2021 and September 2023 providing consulting services for biotechnology, pharmaceutical, and financial services companies. From August 2016 to May 2019, McFarlane served as the chief operating officer of Retrophin now known as Travere Therapeutics. From 2011 to 2016 McFarlane served as vice president and general manager of UCB's U.S. Immunology Business Unit and as vice president for its Global Bone Business Unit in collaboration with Amgen. Prior to his positions at UCB, McFarlane held positions of increasing responsibility with Genzyme and Sangstat Medical Corporation. McFarlane previously served as an officer and enlisted soldier in the United States Army Reserves. He received his B.S. degree and M.S. degree in Nursing from the University of Florida.